BITC Sensitizes Pancreatic Adenocarcinomas to TRAIL-Induced Apoptosis

Christina A. Wicker, Ravi P. Sahu, Kashmira Kulkarni-Datar, Sanjay K. Srivastava, Thomas L. Brown

Research output: Contribution to journalArticlepeer-review

Abstract

Pancreatic adenocarcinoma is an aggressive cancer with a greater than 95% mortality rate and short survival after diagnosis. Chemotherapeutic resistance hinders successful treatment. This resistance is often associated with mutations in codon 12 of the K-Ras gene (K-Ras 12), which is present in over 90% of all pancreatic adenocarcinomas. Codon 12 mutations maintain Ras in a constitutively active state leading to continuous cellular proliferation. Our study determined if TRAIL resistance in pancreatic adenocarcinomas with K-Ras 12 mutations could be overcome by first sensitizing the cells with Benzyl isothiocyanate (BITC). BITC is a component of cruciferous vegetables and a cell cycle inhibitor. BxPC3, MiaPaCa2 and Panc-1 human pancreatic adenocarcinoma cell lines were examined for TRAIL resistance. Our studies show BITC induced TRAIL sensitization by dual activation of both the extrinsic and intrinsic apoptotic pathways.

Original languageAmerican English
JournalCancer Growth and Metastasis
Volume2009
StatePublished - Jan 20 2010

Keywords

  • BITC
  • K-RAS
  • TRAIL resistance
  • chemotherapeutic resistance
  • pancreatic adenocarcinoma

Disciplines

  • Medical Cell Biology
  • Medical Neurobiology
  • Medical Physiology
  • Medical Sciences
  • Medicine and Health Sciences
  • Neurosciences
  • Physiological Processes

Cite this